Japanese Regulator Approves BMS Orencia For Rheumatoid Arthritis
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb announced July 23 that it obtained Japanese approval for Orencia (abatacept) for rheumatoid arthritis patients that are not responding well to current tumor necrosis factor antagonist treatments